Adverse drug events (ADEs) are a major cause of emergency department visits and hospital admissions among the elderly and contribute an additional $3.5 billion to U.S. health care costs.
Adverse events due to high risk drug classes such as anticoagulants, hypoglycemic agents, and opioids are often preventable, and improved management of these medications has been identified as a major public health priority in the Department of Health and Human Services’ National Action Plan for Adverse Drug Event Prevention.
A Community-Based Approach
IPRO has partnered with the Delmarva Foundation of Columbia MD and the Carolinas Center for Medical Excellence of Columbia SC to form the Atlantic Quality Innovation Network (AQIN), under contract with the Centers for Medicare & Medicaid Services (CMS). AQIN is working with providers, pharmacists, pharmacies and stakeholders in New York, the District of Columbia and South Carolina to reduce and monitor adverse drug event rates. To reduce and prevent the incidence of ADEs, we are convening community groups throughout the region that treat Medicare Fee-for-Service (FFS) beneficiaries taking three or more medications, including at least one of these high-risk medications: anticoagulants, diabetic agents and/or opioids.
Patients are at particularly high risk of medication errors and ADEs as they transition between care settings. For more information on effective care transitions and reduction of 30-day hospital re-admissions visit the AQIN Care Transitions page.
- Reduce ADEs by 35 percent per 1,000 Medicare FFS beneficiaries screened by the year 2019.
- Monitor ADE and re-admission rates among Medicare FFS beneficiaries prescribed anticoagulants, hypoglycemic agents or opioids by care setting, state, and region.
AQIN pharmacists have assembled topic-specific coalitions and related resources on targeted high-risk drug classes. For more information select a topic area below: